Organon & CO.
Forward trial catalysts linked to OGN
CSA tracks 1 forward catalyst for Organon & CO. across 1 asset, spanning Phase 3. The nearest is a readout expected Oct 2026 (month precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Plaque Psoriasis, ICD10 Code L40.9 for Psoriasis.
OGN in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Organon & CO. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
2 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| tapinarof | NCT05172726 catalyst | Phase 3 | Active, not recruiting | 2026-10 | Experimental | Organon and Co | Plaque Psoriasis |
| tapinarof | NCT05981118 | Phase 2/3 | Enrolling by invitation | 2027-01 | Active comparator | Wake Forest University Health Sciences | ICD10 Code L40.9 for Psoriasis |
Every trial the CSA sample links to OGN's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →